Thérapies de Conversion

Editorial: Predictive Factors and Survival Outcome of Conversion Therapy for Unresectable Hepatocellular Carcinoma Patients Receiving Atezolizumab and Bevacizumab: Comparative Analysis of Conversion, Partial Response and Complete Response Patients. Author

Aliment Pharmacol Ther . 2024;60 (10) :1469-1470

Résumé

Tous les articles